Garadacimab Uses, Dosage, Side Effects and more
Garadacimab is under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line).
| Attribute | Details |
|---|---|
| Trade Name | Garadacimab |
| Generic | Garadacimab |
| Garadacimab Other Names | Garadacimab, Immunoglobulin G4, anti-(human blood-coagulation factor viia) (human monoclonal CSL312 gamma4-chain), disulfide with human monoclonal CSL312 lambda-chain, dimer |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
